LLY shares dropped 6% after HSBC downgraded the stock, citing persistent U.S. pricing pressure, rising competitive threats and compounded risks to tirzepatide despite continued strong GLP-1 demand. The downgrade signals downside to Lilly's revenue/market-share trajectory and prompted a notable, company-focused sell-off.
LLY shares dropped 6% after HSBC downgraded the stock, citing persistent U.S. pricing pressure, rising competitive threats and compounded risks to tirzepatide despite continued strong GLP-1 demand. The downgrade signals downside to Lilly's revenue/market-share trajectory and prompted a notable, company-focused sell-off.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
